GLOBUS MEDICAL INC. v. SHARP

CourtDistrict Court, E.D. Pennsylvania
DecidedMay 18, 2022
Docket2:22-cv-00383
StatusUnknown

This text of GLOBUS MEDICAL INC. v. SHARP (GLOBUS MEDICAL INC. v. SHARP) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
GLOBUS MEDICAL INC. v. SHARP, (E.D. Pa. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

GLOBUS MEDICAL, INC., : Plaintiff, : CIVIL ACTION : v. : : EDWARD SHARP et al., : No. 22-383 Defendants. :

MEMORANDUM Schiller, J. May 18, 2022 Before the Court is Defendant Edward Sharp’s Motion for Judgment on the Pleadings as to Count VI of Plaintiff’s Complaint. (ECF No. 21.) Sharp, by moving for judgment on the pleadings, in effect asks the Court to cement the meaning of the “repayment obligation” provisions in his compensation agreements at this early juncture, aided only by the language contained within the four corners of the agreements. But these agreements, sloppily drafted as they are, are far from unambiguous. And as explained below, the Court is unable to identify the intent of the parties concerning the provisions at issue due to the rampant ambiguities in each. Extrinsic evidence as produced during discovery will be needed to resolve these ambiguities. Accordingly, the Court will deny Sharp’s motion at this time. I. FACTUAL BACKGROUND A. Sharp’s Agreements with Globus Globus Medical, Inc. (“Globus”) is a medical device company specializing in products that assist surgeons in treating musculoskeletal disorders, specifically those necessitating spinal surgery. (Compl. ¶¶ 1, 15.) A vast network of field sales representatives market and sell Globus’s medical devices to doctors and hospitals. (Id. ¶ 16.) To manage its sales, Globus divides the country into regions, each of which is managed by a Vice President of Sales, and further divides these regions into areas, each managed by an Area Director. (Id. ¶ 17.) Globus then divides these areas into territories, each managed by a Spine Territory Manager. (Id.) Depending on the level of business in that territory, the Spine Territory Manager may be the sole sales representative in that

territory, or they may have further sales representatives working underneath them. (Id.) On January 10, 2020, Globus hired Sharp as Spine Territory Manager for the San Antonio, Texas Territory. (Id. ¶¶ 28-29.) As Spine Territory Manager, Sharp was tasked with “managing and further developing existing Globus customer relationships in the San Antonio Territory, developing relationships with prospective Globus customers, selling Globus products and facilitating their delivery, and managing junior sales representatives on the team.” (Id. ¶ 30.) As a condition of employment, Globus requires all members of its sales force, including Spine Territory Managers, to enter into No Competition and Non-Disclosure Agreements (an “NCNDA”) at the time of hiring. (Id. ¶ 24.) Sharp did so on January 10, 2020 (the “January 2020 NCNDA”). (Id. ¶ 31; Compl. Ex. F.) Sharp then briefly left Globus to work for his former

employer before returning to Globus on February 14, 2020. (Compl. ¶ 31.) Upon his return, he entered into a second NCNDA (the “February 2020 NCNDA”). (Id.) Sharp agreed to the following terms1: • [D]uring the No Competition Period, I will not directly or indirectly participate in, perform services for, be employed by, own any interest in, or otherwise assist a

1 Although Globus represents that Sharp’s February 2020 NCNDA was attached to the Complaint as Exhibit B, (Compl. ¶ 31), Exhibit B is actually an NCNDA between Globus and Andrew Miller. Since the February 2020 NCNDA was not appended to the Complaint, these provisions have been taken from Sharp’s January 2020 NCNDA. However, the Complaint alleges that “[t]he Sharp [February] NCNDA is substantively identical to the Miller NCNDA, and Sharp agreed to the same terms, including the non-competition and non-solicitation provisions.” (Id.) The Court’s review confirmed that the terms enumerated in Sharp’s January 2020 NCNDA mirror the terms from Miller’s NCNDA, and, therefore, Sharp’s February 2020 NCNDA. Competing Company in a position similar in responsibilities to any position I held within the Company in the last twenty-four months prior to the termination of the Relationship or in a position where I could use Confidential Information to the detriment of Globus. • I agree not to directly or indirectly engage in any Competitive Activity with any Hospitals or Medical [Personnel] during the No Competition Period in the NCND Territory. • During the No Competition Period, I agree not to directly or indirectly, either for my benefit or the benefit of another individual or entity, solicit, call on, interfere with, attempt to divert, entice away, service, support, sell to or market to any Hospital in the NCND Territory, or to any Medical Personnel in the NCND Territory who performs any services related to a Competing Product or Service (regardless of whether such services are also provided by the Medical Personnel outside the NCND Territory). • During the No Competition Period, I agree not to directly or indirectly, either for my benefit or the benefit of another individual or entity, employ or offer to employ in any capacity, solicit, call on, attempt to divert, entice away or recommend for employment or contractual relationship with a Competing Company, any individuals who are or were employees, independent contractors, representatives or employees of [Globus] or any of [Globus]’s distributors at any time within the preceding 12 months.2

(Compl. Ex. F ¶¶ 3.1-3.3.) The February 2020 NCNDA contained a choice of law provision mandating that it “shall be enforced as a contract of the Commonwealth of Pennsylvania because Globus’s operational and worldwide headquarters are located in Pennsylvania.” (Id. ¶ 6.5; Compl. ¶ 10.) It further stated that “that the validity, enforceability, construction and interpretation of this NCND Agreement shall be governed by the laws of the Commonwealth of Pennsylvania, without regard to its conflict of law rules.” (Compl. Ex. F ¶ 6.5; Compl. ¶ 10.) Sharp and Globus also executed three agreements concerning Sharp’s compensation (collectively, the “Compensation Agreements”). On February 14, 2020, the same day the February 2020 NCNDA was executed, Sharp and Globus entered into the first of these agreements, labeled by the parties as a Minimum Monthly Guarantee Draw Agreement (the “February 2020

2 Capitalized terms are defined as provided in the NCNDA. MMGDA”). (Id. ¶ 32; Compl. Ex. G.) The February 2020 MMGDA also served as Sharp’s offer letter. (Compl. Ex. G at 2.) It defined Sharp’s territory as “[g]reater San Antonio and Austin” and provided that, for the first twelve months of Sharp’s employment, his compensation would comprise a $75,000 “Base Salary [] plus commission.” (Id. at 2, 6.) After twelve months, Sharp

would no longer receive a salary and instead receive “12% [commission] on all sales split between the super territory [of Greater San Antonio and Austin]” and a minimum monthly guarantee draw (“MMGD”) of “$54,167 per month for months 13-24 of employment.” (Id. at 3.) During that period, if Sharp were to receive less “annual income”—defined as comprising Sharp’s salary, commission, monthly automobile allowances, and bonuses—than the total amount he received via his MMGD payments, Globus would forgive the difference; if Sharp were to receive more annual income than the total amount he received via his MMGD payments, Sharp would keep the excess. (Id.) The February 2020 MMGDA conditioned both Sharp’s salary and eventual MMGD payments on “employment with Globus as an agent or direct employee for a minimum of twenty-

four (24) months [] from the Effective Date [February 17, 2020].” (Id. at 2.) It stated that Sharp’s “salary and MMGD is not earned unless this condition is met” and “[a]ny interim payments made are advances.” (Id.) It further stated that Sharp had to repay Globus “any and all amounts in excess of $10,000 per month in compensation (Salary, Commission, Auto and all eligible Bonuses) paid through the date of separation” should he resign from Globus before February 17, 2022.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Revell v. Port Authority of New York & New Jersey
598 F.3d 128 (Third Circuit, 2010)
Klaxon Co. v. Stentor Electric Manufacturing Co.
313 U.S. 487 (Supreme Court, 1941)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Hullett v. Towers, Perrin, Forster & Crosby, Inc.
38 F.3d 107 (Third Circuit, 1994)
Gay v. CreditInform
511 F.3d 369 (Third Circuit, 2007)
American Eagle Outfitters v. Lyle & Scott Ltd.
584 F.3d 575 (Third Circuit, 2009)
LCI Communications, Inc. v. Wilson
700 F. Supp. 1390 (W.D. Pennsylvania, 1988)
DeWitt County Electric Cooperative, Inc. v. Parks
1 S.W.3d 96 (Texas Supreme Court, 1999)
Madison Construction Co. v. Harleysville Mutual Insurance
735 A.2d 100 (Supreme Court of Pennsylvania, 1999)
Krizovensky v. Krizovensky
624 A.2d 638 (Superior Court of Pennsylvania, 1993)
Pantuso Motors, Inc. v. Corestates Bank
798 A.2d 1277 (Supreme Court of Pennsylvania, 2002)
Banks Engineering Co., Inc. v. Polons
752 A.2d 883 (Supreme Court of Pennsylvania, 2000)
Steuart v. McChesney
444 A.2d 659 (Supreme Court of Pennsylvania, 1982)
Commonwealth v. Musser Forests, Inc.
146 A.2d 714 (Supreme Court of Pennsylvania, 1958)
Peat Marwick Main & Co. v. Haass
818 S.W.2d 381 (Texas Supreme Court, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
GLOBUS MEDICAL INC. v. SHARP, Counsel Stack Legal Research, https://law.counselstack.com/opinion/globus-medical-inc-v-sharp-paed-2022.